Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Not yet recruiting × mirdametinib × Clear all

Phase

Status

Recruiting 3 Terminated 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 1 Glioma 1 Glioblastoma 1

Interventions

Carboplatin 77 Cisplatin 75 Bevacizumab 70 Oxaliplatin 57 Capecitabine 57 tislelizumab 53 Radiotherapy 53 Drug Therapy 52 Gemcitabine 49 Paclitaxel 47 toripalimab 46 pembrolizumab 41 sintilimab 39 Specimen Handling 36 Cyclophosphamide 35 anlotinib 34 130-nm albumin-bound paclitaxel 33 Injections 30 Pemetrexed 27 lenvatinib 26 camrelizumab 25 Surgical Procedures, Operative 25 Magnetic Resonance Spectroscopy 24 Docetaxel 24 Immune Checkpoint Inhibitors 23 Fluorouracil 23 apatinib 22 S 1 (combination) 20 Etoposide 20 Radiosurgery 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07521657 2026-04-13

NF118

University of Alabama at Birmingham

Phase 2 Not yet recruiting

Glioblastoma, Glioma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡